ReviewInternational urogynecology journal2026
Neuromodulation for Lower Urinary Tract Dysfunction: Mechanisms, Modalities, and Patient Selection.
Review in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeLower urinary tract dysfunction (LUTD) includes urgency, frequency, urgency urinary incontinence, voiding symptoms, and nonobstructive urinary retention, with many patients remaining symptomatic after behavioral and pharmacologic therapy. Neuromodulation has a distinct role because it targets aberrant reflex activity and sensory signaling in pelvic afferent pathways and spinal-supraspinal circuits rather than directly altering detrusor contractility or outlet resistance.
methodsThis narrative review synthesizes PubMed/MEDLINE literature, major urological guidelines, and evidence syntheses up to May 2026. Evidence was prioritized by methodological robustness and qualitatively synthesized by modality, LUTD phenotype, durability, treatment burden, safety, and clinical relevance.
resultsSacral neuromodulation (SNM) is the most established implant-based approach, with reported 5-year success of approximately 67-82% in non-neurogenic overactive bladder (OAB), although long-term benefit depends on testing, revision risk, and repeated programming. Smaller and rechargeable pulse generators, MRI-conditional systems, and multi-contact leads are reducing historical barriers and enabling more flexible programming; randomized evidence suggests electrode design can improve short-term response. Tibial nerve stimulation has expanded across clinic-based and home-based workflows. Percutaneous tibial nerve stimulation improves OAB symptoms in sham-controlled trials but requires ongoing visits and maintenance dosing. Transcutaneous approaches reduce procedural burden, although protocol heterogeneity limits comparisons. Implantable tibial neuromodulation provides scheduled home stimulation and shows durable 2-year responder rates in pivotal studies, but comparisons with SNM remain largely indirect. Safety data generally show minor, reversible adverse events.
conclusionNeuromodulation is an important LUTD treatment, but better patient selection, neurogenic risk stratification, standardized outcomes, comparative studies, and physiology-guided programming remain priorities.
Indexed as
Identifiers
42554753What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.